Literature DB >> 17912530

Subcutaneous tunneling of the temporary testing electrode significantly improves the success rate of subchronic sacral nerve modulation (SNM).

Karl-Dietrich Sievert1, Udo Nagele, Juergen Pannek, Daniel Engeler, Markus Kuczyk, Arnulf Stenzl.   

Abstract

Sacral nerve modulation (SNM) is an effective way to treat non-neurogenic dysfunctions of pelvic organs. For over 20 years, this technique has been used for the treatment of overactive bladder, urinary retention, pelvic pain and even more recently, fecal incontinence and constipation. The objective of the study is to improve the fixation of the temporary testing electrode (TTE) in order to obtain more reliable results in the testing phase which should lead to have a comparable success rate as the two-stage implant for a chronic implant. Twenty-eight patients (ratio of sex women:men = 3:1; with overactive bladder, urinary retention, pelvic pain syndrome and fecal incontinence) were evaluated by the modified temporary test electrode (TTE) placement. With the subcutaneous tunneling technique (mean time of evaluation 8.3 days), it is possible to perform percutaneous nerve evaluation (PNE) more effectively with an objective, reliable and less expensive outcome prior to the implantation of the implantable sacral nerve stimulator in almost 80% of the evaluated patients. Because the costs of therapy are not covered by health insurance in all countries, there is a need for an effective and inexpensive way to test and select patients appropriately. The tunneled TTE maintains its place for consistent amplitude during the entire test duration. The modification of placing the TTE produces repayable results. This technique can be performed on an outpatient basis to evaluate sacral nerve modulation as an early treatment option for non-dysfunctions of pelvic organs before they are forwarded to a specialized center for a chronic SNM implantation.

Entities:  

Mesh:

Year:  2007        PMID: 17912530     DOI: 10.1007/s00345-007-0204-5

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  16 in total

Review 1.  Injectable neuromodulatory agents: botulinum toxin therapy.

Authors:  Tara L Frenkl; Raymond R Rackley
Journal:  Urol Clin North Am       Date:  2005-02       Impact factor: 2.241

2.  Current indications for neuromodulation.

Authors:  Firouz Daneshgari; M Louis Moy
Journal:  Urol Clin North Am       Date:  2005-02       Impact factor: 2.241

3.  Long term results of neuromodulation by sacral nerve stimulation for lower urinary tract symptoms: a retrospective single center study.

Authors:  A C van Voskuilen; D J A J Oerlemans; E H J Weil; R A de Bie; Ph E V A van Kerrebroeck
Journal:  Eur Urol       Date:  2006-01-04       Impact factor: 20.096

4.  Buttock placement of the implantable pulse generator: a new implantation technique for sacral neuromodulation--a multicenter study.

Authors:  W A Scheepens; E H Weil; G A van Koeveringe; D Rohrmann; H E Hedlund; B Schurch; E Ostardo; M Pastorello; C Ratto; J Nordling; P E van Kerrebroeck
Journal:  Eur Urol       Date:  2001-10       Impact factor: 20.096

5.  Predictive factors for sacral neuromodulation in chronic lower urinary tract dysfunction.

Authors:  W A Scheepens; M M G J Jongen; F H M Nieman; R A de Bie; E H J Weil; P E V van Kerrebroeck
Journal:  Urology       Date:  2002-10       Impact factor: 2.649

6.  Prolonged sacral neuromodulation testing using permanent leads: a more reliable patient selection method?

Authors:  Thomas M Kessler; Helmut Madersbacher; Gustav Kiss
Journal:  Eur Urol       Date:  2005-01-04       Impact factor: 20.096

Review 7.  Selecting patients for sacral nerve stimulation.

Authors:  Steven W Siegel
Journal:  Urol Clin North Am       Date:  2005-02       Impact factor: 2.241

8.  Canadian experience in sacral neuromodulation.

Authors:  Mohamed Elkelini; Magdy M Hassouna
Journal:  Urol Clin North Am       Date:  2005-02       Impact factor: 2.241

9.  New sacral neuromodulation lead for percutaneous implantation using local anesthesia: description and first experience.

Authors:  Michele Spinelli; Gianluca Giardiello; Martin Gerber; Andrea Arduini; Ubi van den Hombergh; Silvia Malaguti
Journal:  J Urol       Date:  2003-11       Impact factor: 7.450

10.  New percutaneous technique of sacral nerve stimulation has high initial success rate: preliminary results.

Authors:  Michele Spinelli; Gianluca Giardiello; Andrea Arduini; Ubi van den Hombergh
Journal:  Eur Urol       Date:  2003-01       Impact factor: 20.096

View more
  5 in total

Review 1.  Sacral neuromodulation stimulation in fecal incontinence.

Authors:  Tracy L Hull
Journal:  Int Urogynecol J       Date:  2010-12       Impact factor: 2.894

Review 2.  How does sacral modulation work best? Placement and programming techniques to maximize efficacy.

Authors:  Bastian Amend; Mahmoud Khalil; Thomas M Kessler; Karl-Dietrich Sievert
Journal:  Curr Urol Rep       Date:  2011-10       Impact factor: 3.092

3.  Outcomes following percutaneous tibial nerve stimulation (PTNS) treatment for neurogenic and idiopathic overactive bladder.

Authors:  Katarina Ivana Tudor; Jai H Seth; Martina D Liechti; Juliana Ochulor; Gwen Gonzales; Collette Haslam; Zoe Fox; Mahreen Pakzad; Jalesh N Panicker
Journal:  Clin Auton Res       Date:  2018-08-03       Impact factor: 4.435

Review 4.  Contrasting the percutaneous nerve evaluation versus staged implantation in sacral neuromodulation.

Authors:  Chad Baxter; Ja-Hong Kim
Journal:  Curr Urol Rep       Date:  2010-09       Impact factor: 3.092

Review 5.  [Second-line therapy of idiopathic detrusor overactivity. Sacral neuromodulation and botulinum toxin A].

Authors:  B Amend; D Castro-Diaz; E Chartier-Kastler; D De Ridder; K Everaert; M Spinelli; P van Kereebroeck; K-D Sievert
Journal:  Urologe A       Date:  2010-02       Impact factor: 0.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.